Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu-->Pro). 2003

Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
Department of Medical Engineering, University of Applied Sciences (FH) Jena, Carl-Zeiss-Promenade 2, Jena D-07745, Germany. michael.meyer@fh-jena.de

BACKGROUND The exchange of Aalpha 16, Arg for Cys or His is the most common molecular defect in dysfibrinogenemia directly affecting the thrombin cleavage site involved in fibrinopeptide A (FPA) release. Other amino acid exchanges within the fibrinopeptide A have been only rarely reported. METHODS In clinically asymptomatic dysfibrinogenemic patients with low functional plasma fibrinogen (Fg) levels and prolonged thrombin time but normal or slightly prolonged batroxobin (reptilase) time, mutation analysis was carried out by direct sequencing of the coding regions of the three fibrinogen genes. Isolated fibrinogen was functionally characterized for thrombin- or batroxobin-induced fibrinopeptide release and fibrin formation. Fibrinogen and fibrinopeptides were structurally studied by electrophoretic techniques or high-performance liquid chromatography. CONCLUSIONS Molecular analysis revealed heterozygosity for a novel missense mutation T1182C in the FGA gene causing the amino acid exchange Aalpha 9, Leu-->Pro. Fibrin generation induced by thrombin was moderately impaired, whereas batroxobin-induced fibrin formation was almost normal. Release of the abnormal fibrinopeptide A by thrombin was delayed but fibrin monomer aggregation was almost normal. Cleavage of Aalpha chains by batroxobin was only slightly delayed. Fibrinopeptides A of the patient fibrinogen did not show any gross abnormality in chromatographic behaviour. This new molecular variant designated fibrinogen Magdeburg I supports the view that amino acid residue Leu-9 in the Aalpha chain as part of a small hydrophobic cluster is involved in the interaction with an apolar binding site of thrombin, thus adding to our understanding of the thrombin-fibrinogen interaction crucial in coagulation.

UI MeSH Term Description Entries
D007930 Leucine An essential branched-chain amino acid important for hemoglobin formation. L-Leucine,Leucine, L-Isomer,L-Isomer Leucine,Leucine, L Isomer
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005344 Fibrinopeptide A Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin. Fibrinopeptides A
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin
D013918 Thrombin Time Clotting time of PLASMA mixed with a THROMBIN solution. It is a measure of the conversion of FIBRINOGEN to FIBRIN, which is prolonged by AFIBRINOGENEMIA, abnormal fibrinogen, or the presence of inhibitory substances, e.g., fibrin-fibrinogen degradation products, or HEPARIN. BATROXOBIN, a thrombin-like enzyme unaffected by the presence of heparin, may be used in place of thrombin. Reptilase Time,Reptilase Times,Thrombin Times,Time, Reptilase,Time, Thrombin,Times, Reptilase,Times, Thrombin
D015241 Fibrinogens, Abnormal Fibrinogens which have a functional defect as the result of one or more amino acid substitutions in the amino acid sequence of normal fibrinogen. Abnormalities of the fibrinogen molecule may impair any of the major steps involved in the conversion of fibrinogen into stabilized fibrin, such as cleavage of the fibrinopeptides by thrombin, polymerization and cross-linking of fibrin. The resulting dysfibrinogenemias can be clinically silent or can be associated with bleeding, thrombosis or defective wound healing. Abnormal Fibrinogens

Related Publications

Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
March 1985, European journal of biochemistry,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
December 1999, Thrombosis research,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
December 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
March 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
July 2001, Blood,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
March 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
August 2008, Journal of thrombosis and haemostasis : JTH,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
February 2002, Thrombosis and haemostasis,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
May 1977, Thrombosis research,
Michael Meyer, and Gerlinde Kutscher, and Jörg Stürzebecher, and Gabriele Riesener, and Gerd Lutze
September 2002, Thrombosis and haemostasis,
Copied contents to your clipboard!